Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 9/13/2016 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Siggi Olafsson?

Siggi O. Olafsson

President

Teva Pharmaceutical Industries Ltd.

HQ Phone:  +972 3-926-7267

Direct Phone: (215) ***-****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Teva Pharmaceutical Industries Ltd.

5 Basel Street

Petah Tiqwa, Central District,4951033

Israel

Company Description

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world's largest g...more

Background Information

Employment History

Executive Vice President

Durata Therapeutics Inc


Web References(38 Total References)


Goodness gracious me! Time for a management change at Teva - Pharmacloud

www.pharmacloud.co.uk [cached]

The news earlier this week that Siggi Olafsson is leaving Teva, to be succeeded by Dipankar Bhattacharjee (currently head of Teva Generics Europe) comes as something of a surprise, to say the least.
And the timing of the announcement is odd, given that Mr Olafsson hosted an investor day on New York in September at which he laid out the growth plan for the expanded Teva generics division, which he will now not be staying around to deliver. But of course, the deliverability of the plan may be precisely why he is going. The Teva press release says that Siggi will remain with the business until the end of Q1 2017 to ensure an orderly transition, which has been interpreted by some as meaning that the decision to leave has come from him rather than from Teva. In our view, this is unlikely to be the whole story. It is rather more probable that Teva's board feels that someone should carry the can for the company's recent underperformance and that Siggi is the obvious candidate. This is a lot to ask of anyone and there is no evidence that Dipankar will do any better at it than Siggi would have.


Welcome to Pharmacloud Research

www.pharmacloud.co.uk [cached]

Siggi Olafsson
The news earlier this week that Siggi Olafsson is leaving Teva, to be succeeded by Dipankar Bhattacharjee (currently head of Teva Generics Europe) comes as something of a surprise, to say the least. As the architect of Teva's long drawn-out purchase of Allergan's generics business, Actavis, we would have expected him at least to ... Read More


Teva and Celltrion announce exclusive biosimilar commercial partnership

www.biosimilarnews.com [cached]

"This commercial partnership with Celltrion enables Teva to expand into the upcoming wave of biosimilars and build on its strong position in the biosimilar space," said Siggi Olafsson, President & CEO of Global Generic Medicines, Teva Pharmaceuticals.


Welcome to Pharmacloud Research

www.pharmacloud.co.uk [cached]

Siggi Olafsson
The news earlier this week that Siggi Olafsson is leaving Teva, to be succeeded by Dipankar Bhattacharjee (currently head of Teva Generics Europe) comes as something of a surprise, to say the least. As the architect of Teva's long drawn-out purchase of Allergan's generics business, Actavis, we would have expected him at least to ... Read More


www.pharmacloud.co.uk

The news earlier this week that Siggi Olafsson is leaving Teva, to be succeeded by Dipankar Bhattacharjee (currently head of Teva Generics Europe) comes as something of a surprise, to say the least.
And the timing of the announcement is odd, given that Mr Olafsson hosted an investor day on New York in September at which he laid out the growth plan for the expanded Teva generics division, which he will now not be staying around to deliver. But of course, the deliverability of the plan may be precisely why he is going.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory